Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Early Phase Clinical Trials (Phase 1 & Phase 2)

A Single Arm Phase II Study Evaluating the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Tremelimumab in Patients with Metastatic HER2 Negative Breast Cancer: TNBC Expansion Cohort

The main purpose of this study is to determine the effects, both good and/or bad, of MEDI4736 in combination with Tremelimumab in treating metastatic HER2 negative breast cancer.

Status: Accepting New Patients
Principal Investigator: Massimo Cristofanilli

A Phase II, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent malignant glioma with Tremelimumab and Durvalumab (MEDI4736) alone and in combination to determine immunologic changes from treatment.

The main purpose of this trial is to investigate the effects of a new class of drugs that help the patient’s immune system attack their tumor (Glioblastoma Multiforme – GBM). These drugs have already shown benefit in some other cancer types and are now being explored in GBM.

Status: Accepting New Patients
Principal Investigator: Jeffrey Raizer

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

To find out if the study drug INCB059872 is safe and may have beneficial effects in people who have different types of cancer.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

The purpose of this study is to evaluate the safety, as assessed by incidence of DLT, of talimogene laherparepvec in combination with pembrolizumab in subjects w/ previously untreated, unresectable, stage IIIB to IVM1c melanoma.

Status: Accepting New Patients
Principal Investigator: Sunandana Chandra

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification

The main purposes of this study are to evaluate whether combining ABT-414 with usual RT and TMZ treatment controls GBM better than usual RT and TMZ without ABT-414, and whether ABT-414 makes patients live longer.

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888_ Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to find out what effects (good and/or bad) Veliparib has, when added to standard combination therapy of Radiation, Carboplatin, and Paclitaxel, on participants and their non-small cell lung cancer.

Status: Accepting New Patients
Principal Investigator: Victoria Villaflor

A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination with Docetaxel plus Prednisone in Metastatic Castration Resistant Prostate Cancer

This purpose of this study is to determine the safety and effectiveness of a drug called ribociclib in combination with docetaxel plus presnisone to treat metastatic prostate cancer.

Status: Accepting New Patients
Principal Investigator: Maha Hussain

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

The purpose of this study is to test the safety of the combination of multiple drugs: brentuximab vedotin, ipilimumab, and nivolumab, in the treatment of relapsed/refractory Hodgkin lymphoma.

Status: Accepting New Patients
Principal Investigator: Leo Gordon

Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer

The purpose of this study is to see whether a combination of two different drugs – pembrolizumab and capecitabine – is safe, and if it might be effective in treating metastatic breast cancer.

Status: Accepting New Patients
Principal Investigator: William Gradishar

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

This study in being done to determine what affects (good and bad) the therapy blinatumomab has on acute lymphoblastic leukemia (ALL).

Status: Accepting New Patients
Principal Investigator: Shira Dinner

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen

The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination, called Dose-Adjusted EPOCH-R (DA-EPOCH-R, for short).

Status: Accepting New Patients
Principal Investigator: Barbara Pro

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer

The main goals of the research study are to determine the highest safe dose of veliparib in combination (given together) with carboplatin and etoposide, to understand how the body absorbs and handles veliparib when given together with carboplatin and etoposide, and to evaluate the safety and tolerability of veliparib when taken without the chemotherapy combination.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

The purpose of this research study is to compare the good and bad effects of the sequence of immunotherapy (combination of ipilimumab and nivolumab) followed by BRAF inhibitor therapy (combination of dabrafenib and trametinib) if and when the disease becomes resistant, to the sequence of BRAF inhibitor therapy (combination of dabrafenib and trametinib) followed by immunotherapy (combination of ipilimumab and nivolumab) if and when the disease becomes resistant.

Status: Accepting New Patients
Principal Investigator: Sunandana Chandra

A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with Lymphomas Associated with Immunosuppression

The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Phase Ib Study of Nivolumab and Dasatinib in Patients with Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

The purpose of this research study is to determine the MTD of nivolumab when given in combination with dasatinib in patients with relapsed/refractory Ph+ ALL.

Status: Accepting New Patients
Principal Investigator: Shira Dinner

Randomized Phase II Study of Sorafenib with or without Everolimus In Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer

The purpose of this study is to assess additional benefit of treating your cancer with the addition of Everolimus to Sorafenib and whether these two drugs together do not give serious and intolerable side effects. The addition of everolimus to the usual sorafenib might cause more shrinkage of your cancer and might prevent it from growing but it could also cause more side effects than sorafenib alone. This study will allow the researchers to know whether this treatment with 2 drugs is better, the same, or worse than the usual approach (which is sorafenib alone). To be better, the study drugs should increase the time it takes your cancer to progress by four and a half months or more compared to the usual approach. There will be about 56 people taking part in this study.

Status: Accepting New Patients
Principal Investigator: Maria Matsangou

A Phase II Single Arm Study of Palbociclib in Patients with Metastatic HER2-positive Breast Cancer with Brain Metastasis

The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain. And to determine the overall radiographic response rate in the CNS.

Status: Accepting New Patients
Principal Investigator: Cesar Santa-Maria

A Phase 3, MultiCenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

To determine if an investigational agent known as AG-221 is safe and effective in treating Late Stage Acute Myeloid Leukemia, compared with those commonly used treatment options (also called conventional care regimens).

Status: Accepting New Patients
Principal Investigator: Olga Frankfurt

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

The overall purpose of this study is to determine if JCAR017 is safe and effective as a treatment for adults with B-cell Non-Hodgkin Lymphomas that include Diffuse Large B-cell Lymphoma (Transformed DLBCL from indolent histology and Follicular Lymphoma Grade 3B) and Mantle Cell Lymphoma.

Status: Accepting New Patients
Principal Investigator: Leo Gordon

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This purpose of this study is to determine the safety and effectiveness of a drug called tazemetostat to treat cancer

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Phase II Study of Pazopanib with Oral Topotecan in Patients with Metastatic and Non-resectable Soft Tissue and Bone Sarcomas

The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinase A, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)

The main purpose of the study is to determine how safe and tolerable the study drug, Alisertib, is in patients with AMKL and in patients with MF.

Status: Accepting New Patients
Principal Investigator: Brady Stein

SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The main purpose of this study is to find out more about the side effects of MM-121 when combined with docetaxel or pemetrexed, and to learn if cancer cell growth (disease progression) is delayed in people taking MM-121 with docetaxel or pemetrexed.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Prospective, Randomized, Blinded, Placebocontrolled, Phase IIb Trial of an Autologous Tumor Lysate (Tl) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC In Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence

The purpose of this study is to (1) produce and test a vaccine that is made from your tumor cells and white blood cells to determine if it can prevent melanoma recurrence; (2) to look at the safety of the vaccine (what side effects it has); and (3) to look at the immune system’s response to this vaccine.

Status: Accepting New Patients
Principal Investigator: Sunandana Chandra

An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

This study is divided into 2 parts. The main purpose of the first part of this study (phase 1b) is to evaluate the side effects and risks of an investigational drug, TAK-659, to identify the highest dose that can be tolerated safely, and to decide upon the recommended dose for the second part of the study. The second part of this study (phase 2) will evaluate how well AML responds to the investigational drug.

Status: Accepting New Patients
Principal Investigator: Olga Frankfurt

last updated: Wed - October 18, 2017 - 05:45 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.